Perspectives On Screening and early Treatment for Pulmonary Fibrosis
Research type
Research Study
Full title
Perspectives On Screening and early Treatment for Pulmonary Fibrosis: a qualitative study
IRAS ID
319409
Contact name
Laura Fabbri
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
1 years, 2 months, 29 days
Research summary
This study aims to collect research data exploring public and healthcare professionals' experiences and opinions on screening programmes for lung scarring and treatment of lung scarring before it causes symptoms.
The specific aims of this research are:
1. To find what people understand about lung scarring both before it develops noticeable symptoms and also when there is sufficient scarring for diseases caused by Pulmonary Fibrosis to be diagnosed
2. To understand what the public thinks of screening programmes. A specific focus is on designing a screening for lung scarring and possible treatments option before symptoms develop.
3. To understand what healthcare providers think of screening programmes for lung scarring and providing treatment before symptoms develop.
Methods: We will undertake semi-structured interviews that will be conducted face-to-face, via phone, or via video call over 15 months.
Study population: 30 individuals who underwent lung cancer screening, individuals diagnosed with idiopathic pulmonary fibrosis, or first-degree relatives of individuals with pulmonary fibrosis, plus 20 healthcare professionals with >3 years of work experience with lung diseases.These studies will give us insights into the opinions of end service users and help us design subsequent feasibility studies.
REC name
London - Chelsea Research Ethics Committee
REC reference
22/PR/1504
Date of REC Opinion
15 Dec 2022
REC opinion
Further Information Favourable Opinion